Biopharma Quarterly Dealmaking Statistics, Q1 2018
A look at financing, M&A and alliance activity January–March 2018
Executive Summary
Biopharma financing started the year solidly with $16.6 billion in total deal value, a 14% increase over the previous quarter. Q1 2018 biopharma merger and acquisition deal value, led by Cigna's $67 billion buy of Express Scripts, topped even the previous all-time-high set in Q4 2107, while alliances totaled $30.7 billion and featured big oncology and neurology partnerships.
You may also be interested in...
Billion Dollar Bets, Health Care Magic
Investments of over $100 million are now close to becoming the predominant class of venture capital deployed in the life sciences. What is behind this shift in venture investing and how might it impact companies' strategy to attract the big bucks.
BioNTech COO Sean Marett Reveals How To Spend $270M
BioNTech AG raised $270m in a series A venture round at the start of 2018 as it pursues an ambition to create a fully integrated biopharmaceutical company. COO Sean Marett tells Scrip how the funds will be invested.
Incyte/Merck's ECHO-301 Failure Casts More Shadow On IDO Space
Following failure of Incyte/Merck's epacadostat/Keytruda study, NewLink Genetics says it is reviewing its IDO clinical programs.